Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion

Leukemia Research

Volumn 34, Issue 11, 2010, Pages 1410-1416

  Fenaux, Pierre ^a   Bowen, David ^b   Gattermann, Norbert ^c   Hellström Lindberg, Eva ^d   Hofmann, Wolf Karsten ^e   Pfeilstöcker, Michael ^f   Sanz, Guillermo ^g   Santini, Valeria ^h  

^a AVICENNE HOSPITAL   (France)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f HANUSCH HOSPITAL   (Austria)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Azacitidine; High risk; Int 2; MDS; Myelodysplastic syndromes; Recommendations

Indexed keywords

ANTIBIOTIC AGENT; AZACITIDINE; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LAXATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PRIMROSE OIL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN 3 ANTAGONIST; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CONTINUOUS INFUSION; CREAM; CYTOPENIA; DISEASE CLASSIFICATION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; INFECTION; INJECTION SITE REACTION; IRON CHELATION; KARYOTYPE; KIDNEY DISEASE; LIVER DISEASE; LOCAL SKIN REACTION; LOTION; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT MONITORING; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REVIEW; THERAPY DELAY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; EXPERT WITNESS; MYELODYSPLASTIC SYNDROMES; RISK;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; EXPERT TESTIMONY; HUMANS; MYELODYSPLASTIC SYNDROMES; RISK;

EID: 77957018936     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.05.021     Document Type: Review

References (43)

1. Phekoo K.J., Richards M.A., Moller H., Schey S.A. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica 2006, 91(10):1400-1404.
2. Cataldo V.D., Cortes J., Quintas-Cardama A. Azacitidine for the treatment of myelodysplastic syndrome. Expert Rev Anticancer Ther 2009, 9(7):875-884.
3. Itzykson R., Fenaux P. Optimal sequencing of treatments for patients with myelodysplastic syndromes. Curr Opin Hematol 2009, 16(2):77-83.
4. NCCN Clinical Practice Guidelines in Oncology™: Myelodysplastic Syndromes [computer program]. Version 2 2010.
5. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51(2):189-199.
6. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100(7):2292-2302.
7. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114(5):937-951.
8. Balduini C.L., Guarnone R., Pecci A., Centenara E., Ascari E. International prognostic scoring system and other prognostic systems for myelodysplastic syndromes. Blood 1997, 90(10):4232-4234.
9. Malcovati L., Germing U., Kuendgen A., la Porta M.G., Pascutto C., Invernizzi R., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25(23):3503-3510.
10. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89(6):2079-2088.
11. Sekeres M.A., Schoonen W.M., Kantarjian H., List A., Fryzek J., Paquette R., et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008, 100(21):1542-1551.
12. Miller K.B., Kim K., Morrison F.S., Winter J.N., Bennett J.M., Neiman R.S., et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann Hematol 1992, 65(4):162-168.
13. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106(8):1794-1803.
14. Knipp S., Hildebrand B., Kundgen A., Giagounidis A., Kobbe G., Haas R., et al. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer 2007, 110(2):345-352.
15. Quesnel B., Guillerm G., Vereecque R., Wattel E., Preudhomme C., Bauters F., et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998, 91(8):2985-2990.
16. Jiang Y., Dunbar A., Gondek L.P., Mohan S., Rataul M., O'Keefe C., et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009, 113(6):1315-1325.
17. Santini V., Kantarjian H.M., Issa J.P. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001, 134(7):573-586.
18. Santini V. Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes. Expert Rev Hematol 2009, 2(2):121-127.
19. Stresemann C., Bokelmann I., Mahlknecht U., Lyko F. Azacytidine causes complex DNA methylation responses in myeloid leukemia. Mol Cancer Ther 2008, 7(9):2998-3005.
20. Fenaux P., Mufti G.J., Hellström-Lindberg E., Santini V., Finelli C., Giagounidis A., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10(3):223-232.
21. Celgene Europe Ltd. Vidaza® Summary of product characteristics; 2008.
22. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002, 20(10):2429-2440.
23. Silverman L.R., McKenzie D.R., Peterson B.L., Holland J.F., Backstrom J.T., Beach C.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006, 24(24):3895-3903.
24. Silverman L.R., McKenzie D.R., Peterson B.L., Demakos E.P., Malone N.T., Holland J.F., et al. Azacitidine prolongs survival and time to AML transformation in high-risk myelodysplastic syndrome (MDS) patients ≥65 years of age. Blood (ASH Annual Meeting Abstracts) 2005, 106:2524.
25. Kornblith A.B., Herndon J.E., Silverman L.R., Demakos E.P., Odchimar-Reissig R., Holland J.F., et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002, 20(10):2441-2452.
26. Seymour JF, Fenaux P, Silverman LR, Mufti SJ, Hellström-Lindberg E, Santini V, et al. Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2010; in press.
27. Fenaux P., Mufti G.J., Hellström-Lindberg E., Santini V., Gattermann N., Germin U., et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28(4):562-569.
28. Lyons R.M., Cosgriff T.M., Modi S.S., Gersh R.H., Hainsworth J.D., Cohn A.L., et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009, 27(11):1850-1856.
29. Silverman L.R., Holland J.F., Weinberg R.S., Alter B.P., Davis R.B., Ellison R.R., et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 1993, 7(Suppl. 1):21-29.
30. Sekeres M.A., Maciejewski J.P., Donley D.W., Grinblatt D.L., Narang M., Malone J.M., et al. A study comparing dosing regimens and efficacy of subcutaneous to intravenous azacitidine (AZA) for the treatment of myelodysplastic syndromes (MDS). Blood (ASH Annual Meeting Abstracts) 2009, 114:3797.
31. Garcia-Manero G., Gore S.D., Skikne B., Cogle C.R., Ning Y., MacBeth K.J., et al. A Phase 1, Open-Label, Dose-Escalation Study to evaluate the safety, pharmacokinetics, and pharmacodynamics of oral azacitidine in patients with myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). Blood (ASH Annual Meeting Abstracts) 2009, 114(22):117.
32. Silverman L.R., Fenaux P., Mufti G.J., Santini V., Hellström-Lindberg E., Gattermann N., et al. The effects of continued azacitidine (AZA) treatment cycles on response in high-risk patients (Pts) with myelodysplastic syndromes (MDS). Blood (ASH Annual Meeting Abstracts) 2008, 112:227.
33. List A.F., Fenaux P., Mufti G.J., Hellström-Lindberg E., Gore S., Bennett J.M., et al. Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission. J Clin Oncol 2008, 26(Suppl):7006.
34. Santini V., Fenaux P., Mufti G., Hellström-Lindberg E., List A., Silverman L., et al. Patient outcome measures during prolonged survival in patients with high-risk myelodysplastic syndromes (MDS) treated with azacitidine (AZA). J Clin Oncol 2008, 26(Suppl):7028.
35. Zwierzina H., Suciu S., Loeffler-Ragg J., Neuwirtova R., Fenaux P., Beksac M., et al. Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group. Leukemia 2005, 19(11):1929-1933.
36. Santini V, Fenaux P, Mufti GJ, Hellström-Lindberg E, Silverman LB, List A, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol; in press.
37. Platzbecker U., Aul C., Ehninger G., Giagounidis A. Reduction of 5-azacitidine induced skin reactions in MDS patients with evening primrose oil. Ann Hematol 2010, 89(4):427-428.
38. Field T., Perkins J., Huang Y., Kharfan-Dabaja M.A., Alsina M., Ayala E., et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010, 45(2):255-260.
39. Grövdal M., Khan R., Aggerholm A., Antunovic P., Astermark J., Bernell P., et al. Maintenance treatment with 5-azacitidine for patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS (MDS-AML) in complete remission (CR) after induction chemotherapy. Blood (ASH Annual Meeting Abstracts) 2008, 112:223.
40. Gardin C., Prébet T., Bouabdallah K., Caillot D., Guerci A., Raffoux E., et al. A Phase II study of post-remission therapy with azacitidine (AZA) in patients with AML post-MDS and high-risk MDS: a GFM Group study. Blood (ASH Annual Meeting Abstracts) 2009, 114:844.
41. Sekeres M.A., List A.F., Cuthbertson D., Paquette R., Latham D., Afable M., et al. Phase I combination study of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol 2010, 28:2253-2258.
42. Kantarjian H., Giles F., Greenberg P., Paquette R., Wang E., Gabrilove J., et al. Effect of romiplostim in patients (pts) with low or intermediate risk myelodysplastic syndrome (MDS) receiving azacytidine. Blood (ASH Annual Meeting Abstracts) 2008, 112:224.
43. Musto P., Maurillo L., Spagnoli A., Gozzini A., Rivellini F., Lunghi M., et al. Azacitidine for the treatment of lower risk myelodysplastic syndromes: a retrospective study of 74 patients enrolled in an Italian named patient program. Cancer 2010, 116:1485-1494.